echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States

    China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 15, it was learned from the Institute of Microbiology of the Chinese Academy of Sciences that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recently allowed EU member states to use the combination therapy of monoclonal antibodies LY-CoV555 and LY-CoV016 in public health emergencies (" "Antibody cocktail" therapy) to deal with patients with new coronary pneumonia infection, among which, LY-CoV016 was jointly developed by the Institute of Microbiology, Chinese Academy of Sciences and Junshi Biology.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.